Randall Kaye

Dr. Kaye joined Neurana Pharmaceuticals as Chief Medical Officer in October 2019 with over 30 years of experience in the medical field. Prior to Neurana, Dr. Kaye was CMO of Click Therapeutics, Inc. a leader in digital healthcare innovation, where he was involved in the development of software as a prescription medical treatment for a number of conditions that represent significant medical need, including pain, depression, and smoking cessation. Prior to Click, he served as a chief scientific officer of SSI Strategy Holdings LLC, where he oversaw clinical development, medical affairs, and pharmacovigilance. In conjunction with his role at SSI Strategy, he served as CMO of Axsome Therapeutics, Inc. Earlier in his career, Dr. Kaye held the positions of CMO of Avanir Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceutical Co., and vice president of medical affairs of Scios Inc. and InterMune, Inc. He also held clinical development and medical affairs positions at Pfizer Inc.

Dr. Kaye earned an M.D., M.P.H., and B.S. at George Washington University. He was a Research Fellow at Harvard Medical School.